GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2007

Caliper to Explore Novel Indications for Drug Candidates at Pfizer

  • Caliper's Discovery Alliances & Services division will conduct certain in vivo profiling experiments for Pfizer. These will enable Pfizer to explore new indications for some compounds in its R&D pipeline.

    Under the one-year contract, Caliper will utilize its in vivo compound profiling platform to study the effects of acute or chronic drug dosing in mice to try and uncover new uses for compounds already in development.

    "On average, a drug has six and a half to seven years of patent life remaining after being launched," says Kevin Hrusovsky, president and CEO of Caliper Life Sciences. "Our portfolio of advanced in vitro and in vivo capabilities is being leveraged by pharmaceutical companies to explore the potential for drugs to treat indications beyond their original design."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?